Sometime in early 2011, SourceMDx, liquidated all of its assets and discontined business operations. Previously known as Source Precision Medicine and with facilites also in MA, Source MDx had been focused on development of RNA-based biomarkers and companion diagnostics in inflammation related therapeutic areas including oncology, cardiovascular, autoimmune and infectious diseases. The firm pioneered precision measurement and clinical utility of RNA-based biomarkers in the characterization of inflammation and immune response: demonstrating the ability to monitor an individualâs health, disease status and response to therapy at the molecular level based on RNA from whole blood, tissue and biofluid samples. While active, the firm had available or in development custom primers and probes for over 1,450 genes specific to oncology (over 600 genes), cardiovascular disease (over 300 genes), autoimmune diseases (over 400 genes) and infectious diseases (over 150 genes). The precise and calibrated custom primers and probes with high amplification efficiencies werethe basis of the firm's multi-gene QPCR assays: Source MDx Precision Profilesâ¢. The firm also wasin development of healthy normals reference datasets (n=30 to 300) for the over 1,450 genes in these focused therapeutic areas. A comprehensive patent portfolio starting when the firm was launched in 1998, Source MDxâs gene expression technology and healthy normals reference datasets. Source MDx used its patented molecular diagnostic system to monitor an individualâs health, disease status and response to therapy at the molecular level based on RNA from whole blood or tissue samples. Source completed over 140 preclinical and clinical projects for more than 30 pharmaceutical and biotechnology companies. Source MDx analyzed over one million gene expression measurements for 22 diseases. Source MDx marketed its molecular biomarker services to pharmaceutical and biotechnology companies for drug development and companion patient care diagnostics focused on inflammation and immune response genes for oncology, cardiovascular, autoimmune and infectious diseases. Source markets over 30 patented disease and pathway-specific biomarker panels (6 to 96 genes) that are used in both preclinical and clinical drug development. After the firm discontinued business operations, fellow SBIR Awardee DxTerity bought ehf firm's canvcer diagn
